CRBU: Bathi resik saben saham (EPS TTM) Caribou Bio

The fundamental TTM net income per share for Caribou Biosciences (CRBU) on GURU.Markets reflects business development within an autonomous product cycle, where the -1.03 mark records this metric. Caribou Biosciences develops unique CRISPR platforms to combat cancer, securing patent protection and capital from partners. However, a lack of sales leaves the company dependent on external financing, as the research stage precludes predictable cash flows.
Caribou Biosciences - rincian analitis lan metrik utama (CRBU)

This indicator reflects the annual net profit of Caribou Biosciences (CRBU) distributed per share, allowing for an assessment of the actual return on capital regardless of the total issuance volume. By analyzing the TTM net income per share of Caribou Biosciences (CRBU), an investor can see how CRISPR development costs in partnership with AbbVie impact the financial result, determining the risk of purchasing the asset at a local peak in profitability.